It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

After the Centers for Medicare & Medicaid Services established higher reimbursement for the repair of anterior abdominal ...

Warren Buffett has long been a proponent of value investing. This strategy has helped him amass a personal fortune of around ...

AbbVie has made another bolt-on deal in the ... Activation of the receptor reprogrammes the cells into less inflammatory behaviour and could have potential as a therapeutic strategy for chronic ...

AbbVie has filed with the FDA to extend the ... limited to people with depression as well as suicidal ideation and behaviour. Spravato was held up as a potential blockbuster at one point, but ...

Digital Matrix Systems, Inc. (DMS), a leading provider of data and analytics solutions, is excited to announce its participation as a sponsor of the CBA LIVE 2025 conference, taking place March 17 ?

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...

AbbVie and Xilio Therapeutics have announced a collaboration to develop innovative tumor-activated immunotherapies, including masked T-cell engagers, utilizing Xilio’s proprietary technology ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host ...

Credit: Studio Romantic/Shutterstock. AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people ...